T. Rowe Price Associates
KRTX

T. Rowe Price Associates’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

T. Rowe Price Associates’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,961,587
Closed -$621M – 2993
2023
Q4 		$621M Sell
1,961,587
-773,251
-28% -$150M 0.08% 224
2023
Q3 		$462M Buy
2,734,838
+73,346
+3% +$13.8M 0.07% 247
2023
Q2 		$577M Buy
2,661,492
+179,932
+7% +$38.5M 0.08% 229
2023
Q1 		$451M Buy
2,481,560
+118,256
+5% +$22.6M 0.07% 255
2022
Q4 		$464M Buy
2,363,304
+147,158
+7% +$31.6M 0.07% 243
2022
Q3 		$498M Buy
2,216,146
+191,307
+9% +$38.7M 0.08% 227
2022
Q2 		$256M Sell
2,024,839
-86,395
-4% -$9.93M 0.03% 413
2022
Q1 		$268M Buy
2,111,234
+155,868
+8% +$17.5M 0.03% 453
2021
Q4 		$256M Buy
1,955,366
+114,735
+6% +$14.8M 0.02% 490
2021
Q3 		$225M Buy
1,840,631
+57,363
+3% +$6.62M 0.02% 513
2021
Q2 		$203M Buy
1,783,268
+92,493
+5% +$10.8M 0.02% 552
2021
Q1 		$203M Buy
1,690,775
+266,614
+19% +$30.2M 0.02% 549
2020
Q4 		$145M Buy
1,424,161
+49,073
+4% +$4.55M 0.01% 608
2020
Q3 		$106M Buy
1,375,088
+8,478
+0.6% +$722K 0.01% 638
2020
Q2 		$152M Sell
1,366,610
-453,333
-25% -$39.4M 0.02% 531
2020
Q1 		$131M Buy
1,819,943
+1,088,336
+149% +$93.1M 0.02% 506
2019
Q4 		$55.1M Buy
731,607
+273,626
+60% +$12M 0.01% 884
2019
Q3 		$7.47M Buy
457,981
+4,607
+1% +$89.5K ﹤0.01% 1328
2019
Q2 		$9.08M Buy
+453,374
New +$9.08M ﹤0.01% 1328

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

T. Rowe Price Associates's KRTX Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 1,961,587 shares — an estimated $621M sold.

T. Rowe Price Associates first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $621M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • T. Rowe Price Associates reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,961,587 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $621M.
  • T. Rowe Price Associates first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • T. Rowe Price Associates's Karuna Therapeutics, Inc. Common Stock position peaked at $621M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.